December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

20.67 -0.08 (-0.39%)
Streaming Delayed Price Updated: 9:48 AM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innoviva, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva (INVA): Affordable Growth Stock at a Reasonable Valuation ↗
Via Chartmill
Innoviva Inc (NASDAQ:INVA): A Decent Value Play with Strong Fundamentals ↗
Via Chartmill
INNOVIVA INC (NASDAQ:INVA): A Strong Growth Stock Poised for a Technical Breakout ↗
Via Chartmill
News headline image
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
From Nortiva Bio, Inc.
Via Business Wire
Innoviva Inc (NASDAQ:INVA): A GARP Standout with 470% EPS Growth and a P/E of Just 6.05 ↗
Via Chartmill
INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals ↗
Via Chartmill
Innoviva Inc (NASDAQ:INVA) Screened as a Top Value Stock with Strong Fundamentals ↗
Via Chartmill
News headline image
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market. 
Via The Motley Fool
Topics Regulatory Compliance
INNOVIVA INC (NASDAQ:INVA) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗
Via Chartmill
Innoviva Inc (NASDAQ:INVA) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Beyond The Numbers: 5 Analysts Discuss Innoviva Stock ↗
 
Via Benzinga
News headline image
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
3 Bargain-Cheap Small Caps Worth a Second Look ↗
Via MarketBeat
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗
Via MarketBeat
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
Value Investing Case Study: INNOVIVA INC (NASDAQ:INVA) ↗
Discover Innoviva (INVA), a potential value stock with strong fundamentals. Its attractive valuation, healthy balance sheet, and solid profitability suggest it trades below intrinsic worth. 
Via Chartmill
News headline image
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
From Innoviva Specialty Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.